NCT01280565View on ClinicalTrials.gov

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

PHASE3TerminatedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Metastatic Melanoma
Interventions
DRUG

Masitinib

Masitinib 7.5 mg/kg/day

DRUG

Dacarbazine

IV bolus at 1,000 mg/m2 once every 3 weeks

Trial Locations (9)

13274

Hôpital Sainte Marguerite, Marseille

20141

Istituto Europeo di Oncologia, Milan

28204

Blumenthal Cancer Centre, Charlotte

33075

Hôpital Saint Andre, Bordeaux

46014

Hospital General de Valencia, Valencia

48149

Klinik und Poliklinik für Hautkrankheiten, Münster

72037

Centre Hospitalier LE MANS, Le Mans

115478

N.N.Blokhin Russian Cancer Research Centre, Moscow

500 12

University Hospital Hradec Králové, Hradec Králové

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY